Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$477.85K
12.99K shares · 0.0% of portfolio
UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Princeton, United States and has 300 employees. The company is worth $1.72B. Revenue was $109.79M in fiscal 2025, up 21.4% from the year before. It reported a net loss of $153.49M. The share price is 30.8% below its 52-week high of $50.81. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Steve Cohen (Point72 Asset Management), at $56.14M. In that quarter, 2 of them opened or added to the position and 3 reduced it. Over the last 30 days, company insiders sold $80.79K of its stock on the open market and bought none.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +185.9% over 5Y.
today you would have $2,009.30▲ +100.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 9 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $23.42 | $10.65 | $15.00 | $8.87 | $9.51 | $18.02 | $33.37 | $43.06 | $37.21 | |
| P/S | 10.4x | 10.4x | 5.4x | 6.6x | 3.2x | 4.5x | 34.0x | 39219.0x | 781.7x | 62.7x |
| P/B | 7.5x | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MESOMesoblast Ltd | $13.28 | — | 3.0x | 0.00% | -9.86% | $1.72B |
| ALVOAlvotech | $4.79 | — | — | 0.00% | — | $1.71B |
| PVLAPalvella Therapeutics Inc | $120.30 | — | 8.0x | 0.00% | -46.63% | $1.73B |
| HCSGHealthcare Services Group Inc | $24.79 |
| — |
| 25.6x |
| 4.2x |
| 3.9x |
| 9.8x |
| 7.5x |
| EPS | -$3.19 | -$2.96 | -$3.55 | -$4.81 | -$4.96 | -$5.90 | -$5.12 | -$4.80 | -$2.14 |
| Profit margin | -230.67% | -139.81% | -140.35% | -123.61% | -170.58% | -230.67% | -1088.94% | -584144.44% | -6707.18% | -245.16% |
| ROE | -83.98% | — | — | — | — | -1317.25% | -133.34% | -58.32% | -83.98% | -29.19% |
Median of the years shown; P/E years above 200x are left out.
| 16.8x |
| 3.2x |
| 0.00% |
| 24.69% |
| $1.7B |
| SEPNSepterna, Inc. | $36.35 | — | 4.3x | 0.00% | -6.34% | $1.7B |
| SNDASonida Senior Living Inc | $35.29 | — | 1.9x | 0.00% | -25.24% | $1.7B |